Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Exclusive News from MarketBeat.com A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHSubmitted by Nathan Reiff. Publication Date: 2/12/2026. 
Summary - AstraZeneca, Edwards Lifesciences, and Zimmer Biomet all reported earnings on the same day, but with vastly different results.
- Of these, AstraZeneca's impressive oncology medicine sales growth stands out, having driven significant top-line growth.
- Edwards and Zimmer both saw notable successes in the latest quarter, but also face sizable challenges.
More than just a financial check-up, earnings for companies in the healthcare sector offer investors a key window into a firm's pipeline and development progress. Even well-established, stable firms can surprise with growth after the release of a new blockbuster drug or medical device, and earnings periods are an opportunity for management to provide insight and commentary beyond what investors might glean from FDA approval notices. When healthcare companies release earnings reports on the same day, it can be a busy time for investors trying to sort through the notable news and plan trades. On Feb. 10, 2025, three major names in the sector—AstraZeneca (NASDAQ: AZN), Edwards Lifesciences (NYSE: EW), and Zimmer Biomet (NYSE: ZBH)—all reported full-year and Q4 2025 results. Below are the highlights and takeaways for healthcare investors planning their next moves. AstraZeneca Firms Up Cancer Business in a Strong Overall Quarterly Performance In 1999, Sutter Hill Ventures made a bold bet on Nvidia before anyone had heard of it. Now, they're going all-in on Nvidia's hush-hush partner that's powering their new Blackwell chip. Discover the little-known company that's attracting massive investments from the visionaries behind Nvidia's 100,000% rise. Unlock the hidden key to AI's future. U.K.-based AstraZeneca closed out 2025 by reinforcing its position as a leading provider of cancer medicines: oncology accounted for roughly 44% of product sales in the fourth quarter. Sales of key oncology drugs such as Imfinzi and Enhertu rose by as much as 48% year-over-year (YOY), helping drive total revenue up 8.6% to $58.7 billion for the quarter. After-tax profits rose alongside revenue, climbing to $10.2 billion from $7 billion in the prior-year quarter, and the company's board declared a second interim dividend that was 7 cents higher than last year's. Investors also have a robust pipeline to watch: management said 20 Phase 3 readouts are expected in 2026, and the firm forecasted solid increases for both total revenue and core earnings per share (EPS) for the full year. In the hours after its strong earnings release, AZN shares rose nearly 3%. While 10 of 11 analysts rate AZN a Buy or equivalent, some on Wall Street have questioned the firm's valuation—the consensus price target of $95.75 implies roughly a 51% decline from current levels. TAVR Momentum Fuels Edwards Sales Growth, Though Investors Should Be Mindful of Earnings and Margin Limits Edwards makes replacement heart valves and related surgical devices and monitoring systems. The firm's Q4 2025 results were broadly positive, with sales up 13.3% YOY driven by strong transcatheter aortic valve replacement (TAVR) demand and traction for the latest SAPIEN valve. However, adjusted EPS missed analyst expectations and gross profit margin fell 0.8% YOY, tempering some of the upside from revenue growth. Despite the mixed elements, Edwards reiterated confidence in its prior 2026 outlook, which calls for sales growth of 8%–10% YOY and EPS between $2.90 and $3.05. EW shares traded above $80 in after-hours action—about 4% higher than the prior close—following the announcement. About two-thirds of analysts covering EW rate the shares a Buy, and the consensus price target of $96.77 suggests roughly 25% upside. Orthopedic Demand Remains High, But Zimmer Faces Some Headwinds Going Forward Zimmer Biomet, a maker of joint and bone replacement systems and implants, saw its shares rise more than 3% following an earnings release that reported EPS of $2.42—$0.04 above consensus—and revenue of $2.2 billion, nearly 11% higher YOY and slightly ahead of expectations. Strong demand for orthopedic products supported both top- and bottom-line growth. The company is also shifting to focus more heavily on the U.S. market, which represents close to 60% of its business. With insured-patient utilization rising, demand for Zimmer's products should remain robust in the near term. That said, Zimmer expects tariffs to continue pressuring margins and could weigh on EPS and revenue in 2026. Management issued relatively conservative guidance in the latest report, outlining adjusted EPS of $8.30–$8.45 and an expected free-cash-flow improvement of 8%–10%. Before the earnings release, analysts were divided on Zimmer: the consensus rating was Hold, despite projected upside of about 15%.
| 
